Loading
IONC102 is an experimental RNA immunotherapy from iOncologi that is being tested in an early trial in glioblastoma.
IONC102 is iOncologi's multilamellar RNA nanocomplex paired with AI-optimised, off-the-shelf antigens, which the company says is in a phase 1 trial in glioblastoma. The trial was not matched to a registry record in OnCo, so no cancer link is recorded.
RNA delivered in multilamellar lipid particles to prime a broad immune response, paired with off-the-shelf tumour antigens, as described by iOncologi.
1.IONC102 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"IONC102" OR ABSTRACT:"IONC102") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IONC102, not a curated reading list.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/